Kidney disease biotech NephroGenex sets terms for $40 million IPO

By
A A A

NephroGenex, a clinical-stage biotech developing treatments for kidney disease, announced terms for its IPO on Tuesday. The Research Triangle Park, NC-based company plans to raise $40 million by offering 3.1 million shares at a price range of $12 to $14. At the midpoint of the proposed range, NephroGenex would command a market value of $115 million.

NephroGenex, which was founded in 2004, plans to list on the NASDAQ under the symbol NRX. NephroGenex initially filed confidentially on November 8, 2013. Aegis Capital is the sole bookrunner on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: NRX

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

9,567,042
  • $100.25 ▼ 1.36%
8,100,757
  • $13.85 ▲ 30.78%
7,811,630
  • $41.98 ▼ 1.34%
4,948,860
  • $74.40 ▼ 0.24%
4,457,400
  • $3.60 ▲ 0.42%
4,267,558
  • $17.3625 ▲ 4.97%
4,006,775
  • $16.73 ▼ 0.06%
3,389,057
  • $25.1101 ▲ 0.20%
As of 9/16/2014, 09:42 AM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com